ArticleCureus2022
Analysis of a Long Non-coding RNA associated Signature to Predict Survival in Patients with Bladder Cancer.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- LncRNA SOX21-AS1 is associated with poor prognosis and immunomodulation in glioblastoma.Translational cancer research · 2026Article
- New Challenges in Bladder Cancer Diagnosis: How Biosensing Tools Can Lead to Population Screening Opportunities.Sensors (Basel, Switzerland) · 2024Review
- The Role of Long Non-Coding RNF144A-AS1 in Cancer Progression.Cell biochemistry and biophysics · 2024Review
- A combination of cuproptosis and lncRNAs predicts the prognosis and tumor immune microenvironment in cervical cancer.Discover oncology · 2024Article
- Long non-coding RNA GRASLND links melanoma differentiation and interferon-gamma response.Frontiers in molecular biosciences · 2024Article
- A new biomarker panel of ultraconserved long non-coding RNAs for bladder cancer prognosis by a machine learning based methodology.BMC bioinformatics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study aimed to find a potential long non-coding RNA (lncRNA) model related to survival in bladder cancer by analyzing data in The Cancer Genome Atlas (TCGA).
methodsWe downloaded the gene expression data from the TCGA and analyzed the differentially expressed lncRNAs (DELs) between tumor and normal tissues. Patients were divided into training and testing groups, and a prognostic risk score model with lncRNAs was constructed by using data in the training group using multivariate Cox and lasso regression analysis. We divided patients into high-and low-risk groups according to the median value in the lncRNA signature model. Survival and receiver operating characteristic (ROC) curves were visualized in both groups. Further, we validated the model in the testing group.
resultsWe screened 169 DELs for bladder cancer. The univariate Cox regression analysis showed that 13 lncRNAs were associated with prognosis with a
conclusionsThe study illustrated a significant lncRNA signature and indicated the risk score Cox model could be an important biomarker to predict the prognosis of bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.